1.93
2.53%
-0.05
시간 외 거래:
1.91
-0.02
-1.04%
전일 마감가:
$1.98
열려 있는:
$2
하루 거래량:
643.56K
Relative Volume:
1.11
시가총액:
$27.14M
수익:
$709.00K
순이익/손실:
$-21.41M
주가수익비율:
-2.0316
EPS:
-0.95
순현금흐름:
$-19.70M
1주 성능:
-11.06%
1개월 성능:
-11.87%
6개월 성능:
+50.78%
1년 성능:
-89.84%
Longeveron Inc Stock (LGVN) Company Profile
명칭
Longeveron Inc
전화
305-302-7158
주소
1951 NW 7TH AVENUE, MIAMI
LGVN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
LGVN | 1.93 | 27.14M | 709.00K | -21.41M | -19.70M | -0.95 |
VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Longeveron Inc 주식(LGVN)의 최신 뉴스
We're Keeping An Eye On Longeveron's (NASDAQ:LGVN) Cash Burn Rate - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires New Stake in Longeveron Inc - GuruFocus.com
The Escalator: Sanofi, Longeveron, Geron and more - MM+M Online
Earnings call: Longeveron Q3 2024 results show promise in regenerative medicine - Investing.com
Longeveron Inc. (NASDAQ:LGVN) Q3 2024 Earnings Call Transcript - Insider Monkey
Longeveron reports Q3 EPS (34c), consensus (44c) - TipRanks
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
LGVNLongeveron Inc. Latest Stock News & Market Updates - StockTitan
A Look Ahead: Longeveron's Earnings Forecast - Benzinga
Longeveron names Devin Blass as new CTO - Investing.com
Longeveron names Devin Blass as new CTO By Investing.com - Investing.com UK
Longeveron Taps Devin Blass As CTO And SVP Of CMC - Contract Pharma
Longeveron Taps Devin Blass As CTO And SVP Of Chemistry, Manufacturing And Controls - Contract Pharma
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC) - The Manila Times
Longeveron Strengthens Leadership: Key Executive Hire Ahead of Critical BLA Submission | LGVN Stock News - StockTitan
Earnings To Watch: Longeveron Inc (LGVN) Reports Q3 2024 Result - Yahoo Finance
Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 - StockTitan
Peeling Back The Layers: Exploring Longeveron Through Analyst Insights - Benzinga
Longeveron presents Alzheimer's therapy data at CTAD24 - Investing.com
Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) - The Manila Times
Longeveron presents Alzheimer's therapy data at CTAD24 By Investing.com - Investing.com UK
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) - StockTitan
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting - ForexTV.com
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting - GlobeNewswire Inc.
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Why has Longeveron stock tripled in two days? - MSN
Euro FX (E6N18) Quote - The Globe and Mail
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
Scholastic Corp (SCHL-Q) QuotePress Release - The Globe and Mail
LGVN’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
LGVNRLongeveron Inc. Latest Stock News & Market Updates - StockTitan
Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) - ForexTV.com
Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) - The Manila Times
Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected - GlobeNewswire
Renaissance Technologies LLC Invests $236,000 in Longeveron Inc. (NASDAQ:LGVN) - Defense World
Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting - The Manila Times
Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting - GlobeNewswire
Longeveron to Present at the UBS Virtual Organ Restoration and Cell Therapy Day - Marketscreener.com
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day - The Manila Times
Longeveron to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - Marketscreener.com
Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - The Manila Times
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) to Participate at the Cell & Gene Meeting on the Mesa - MSN
Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa - The Manila Times
Longeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa - StockTitan
Lamb Weston (LW) Scheduled to Post Quarterly Earnings on Tuesday - Defense World
Analysts review Longeveron Inc’s rating - Knox Daily
Lamb Weston (NYSE:LW) Price Target Raised to $75.00 - Defense World
Ratios Reveal: Breaking Down Longeveron Inc (LGVN)’s Financial Health - The Dwinnex
In the Green: Longboard Pharmaceuticals Inc (LBPH) Closes at 33.89, Up/Down 1.47 from Previous Day - The Dwinnex
Was there any good news for Longeveron Inc (LGVN) stock in the last session? - US Post News
Was Longboard Pharmaceuticals Inc (LBPH)’s session last reading good? - US Post News
Longeveron Inc (LGVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Longeveron Inc 주식 (LGVN) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Hare Joshua | Chief Scientific Officer |
Apr 11 '24 |
Buy |
2.35 |
42,553 |
100,000 |
633,280 |
Hashad Mohamed Wa'el Ahmed | Chief Executive Officer |
Apr 11 '24 |
Buy |
2.35 |
10,638 |
24,999 |
19,616 |
Soffer Rock | Director |
Apr 10 '24 |
Buy |
2.35 |
106,383 |
250,000 |
176,619 |
Soffer Rock | Director |
Apr 11 '24 |
Buy |
2.35 |
31,915 |
75,000 |
208,534 |
Ross Cathy | Director |
Jan 10 '24 |
Buy |
1.31 |
5,000 |
6,544 |
10,000 |
Baluch Khoso | Director |
Dec 29 '23 |
Buy |
1.43 |
8,322 |
11,915 |
15,000 |
Baluch Khoso | Director |
Dec 28 '23 |
Buy |
1.40 |
1,678 |
2,342 |
6,678 |
PFEFFER JEFFREY | Director |
Dec 28 '23 |
Buy |
1.35 |
10,000 |
13,500 |
15,000 |
자본화:
|
볼륨(24시간):